Elevidys Side Effects
Generic name: delandistrogene moxeparvovec
Medically reviewed by Drugs.com. Last updated on Jun 28, 2024.
Note: This document provides detailed information about Elevidys Side Effects associated with delandistrogene moxeparvovec. Some dosage forms listed on this page may not apply specifically to the brand name Elevidys.
Applies to delandistrogene moxeparvovec: intravenous suspension.
Serious side effects of Elevidys
Along with its needed effects, delandistrogene moxeparvovec (the active ingredient contained in Elevidys) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking delandistrogene moxeparvovec:
More common side effects
- black, tarry stools
- bleeding gums
- blood in the urine or stools
- pinpoint red spots on the skin
- unusual bleeding or bruising
Incidence not known
- chest pain or discomfort
- cough
- dark urine
- fast heartbeat
- fever and chills
- loss of appetite
- muscle pain
- nausea or vomiting
- redness or swelling in the ear
- sore throat
- stomach pain, severe
- stuffy or runny nose
- trouble breathing
- unusual tiredness or weakness
- yellow eyes or skin
For healthcare professionals
Applies to delandistrogene moxeparvovec: intravenous kit.
General adverse events
The most common adverse reactions occurring in greater than 5% of patients included vomiting, nausea, liver function test increased, pyrexia, and thrombocytopenia. Adverse reactions were typically seen within the first 2 weeks (nausea, vomiting, thrombocytopenia, pyrexia) or within the first 2 months (immune-mediated myositis, liver function test increased).[Ref]
Cardiovascular
- Frequency not reported: Myocarditis[Ref]
Gastrointestinal
- Very common (10% or more): Vomiting, occurring as early as on the day of infusion (up to 65%), nausea (up to 40%)[Ref]
Hematologic
- Very common (10% or more): Thrombocytopenia (a transient, mild, asymptomatic decrease in platelet counts, 12%)[Ref]
Hepatic
- Very common (10% or more): Liver function test increased, including increased AST, ALT, GGT, GLDH, hepatic enzymes, transaminases, and blood bilirubin (up to 37%)
- Frequency not reported: Acute serious liver injury[Ref]
Immunologic
- Very common (10% or more): Elevated anti-AAVrh74 total binding antibodies titers (100%)[Ref]
Musculoskeletal
- Frequency not reported: Immune-mediated myositis[Ref]
Other
- Very common (10% or more): Pyrexia (up to 24%)
References
1. (2023) "Product Information. Elevidys (10-10.4 kg) (delandistrogene moxeparvovec)." Sarepta Therapeutics
Frequently asked questions
More about Elevidys (delandistrogene moxeparvovec)
- Check interactions
- Compare alternatives
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous uncategorized agents
Patient resources
Professional resources
Related treatment guides
Further information
Elevidys side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.
